Induction of immune tolerance to facilitate β cell regeneration in type 1 diabetes
被引:12
|
作者:
Pasquali, Lorenzo
论文数: 0引用数: 0
h-index: 0
机构:
Univ Pittsburgh, Sch Med, Div Immunogenet, Dept Pediat, Pittsburgh, PA 15213 USA
Univ Genoa, Inst G Gaslini, Dept Pediat, I-16174 Genoa, ItalyUniv Pittsburgh, Sch Med, Div Immunogenet, Dept Pediat, Pittsburgh, PA 15213 USA
Pasquali, Lorenzo
[1
,2
]
Giannoukakis, Nick
论文数: 0引用数: 0
h-index: 0
机构:
Univ Pittsburgh, Sch Med, Div Immunogenet, Dept Pediat, Pittsburgh, PA 15213 USA
Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USAUniv Pittsburgh, Sch Med, Div Immunogenet, Dept Pediat, Pittsburgh, PA 15213 USA
Giannoukakis, Nick
[1
,3
]
Trucco, Massimo
论文数: 0引用数: 0
h-index: 0
机构:
Univ Pittsburgh, Sch Med, Div Immunogenet, Dept Pediat, Pittsburgh, PA 15213 USAUniv Pittsburgh, Sch Med, Div Immunogenet, Dept Pediat, Pittsburgh, PA 15213 USA
Trucco, Massimo
[1
]
机构:
[1] Univ Pittsburgh, Sch Med, Div Immunogenet, Dept Pediat, Pittsburgh, PA 15213 USA
A definitive cure for type 1 diabetes is currently being pursued with enormous effort by the scientific community Different strategies are followed to restore physiologic production of insulin in diabetic patients. Restoration of self-tolerance remains the milestone that must be reached in order to move a step further and recover a cell source capable of independent and functional insulin production. Multiple strategies aimed at modulation of both central and peripheral immunity must be considered. Promising results now show that the immune system can be modulated in a way that acquisition of a "diabetes-suppressive" phenotype is possible. Once self-tolerance is achieved, reversal of the disease may be obtained by simply allowing physiologic rescue and/or regeneration of the beta cells to take place. Given that these outcomes have already been confirmed in humans, refinement of existing protocols along with novel methods adapted to T1DM reversal will allow translation into clinical trials. (c) 2007 Published by Elsevier B.V.
机构:
Novo Nordisk Res Ctr Seattle Inc, Global Drug Discovery, Diabet & Kidney Dis Type 1, Seattle, WA USANovo Nordisk Res Ctr Seattle Inc, Global Drug Discovery, Diabet & Kidney Dis Type 1, Seattle, WA USA
Wesley, Johnna D.
Pagni, Philippe P.
论文数: 0引用数: 0
h-index: 0
机构:
Novo Nordisk Res Ctr Seattle Inc, Global Drug Discovery, Diabet & Kidney Dis Type 1, Seattle, WA USANovo Nordisk Res Ctr Seattle Inc, Global Drug Discovery, Diabet & Kidney Dis Type 1, Seattle, WA USA
Pagni, Philippe P.
Bergholdt, Regine
论文数: 0引用数: 0
h-index: 0
机构:
Clin Drug Dev, Diabet & Funct Insulins Type 1, Seattle, WA USANovo Nordisk Res Ctr Seattle Inc, Global Drug Discovery, Diabet & Kidney Dis Type 1, Seattle, WA USA
Bergholdt, Regine
Kreiner, Frederik Flindt
论文数: 0引用数: 0
h-index: 0
机构:
Novo Nordisk AS, Global Chief Med Off, Soborg, DenmarkNovo Nordisk Res Ctr Seattle Inc, Global Drug Discovery, Diabet & Kidney Dis Type 1, Seattle, WA USA
Kreiner, Frederik Flindt
von Herrath, Matthias
论文数: 0引用数: 0
h-index: 0
机构:
Novo Nordisk AS, Global Chief Med Off, Soborg, Denmark
La Jolla Inst Immunol, Ctr Diabet Type 1, La Jolla, CA USANovo Nordisk Res Ctr Seattle Inc, Global Drug Discovery, Diabet & Kidney Dis Type 1, Seattle, WA USA
机构:
Univ Calif San Francisco, Sean N Parker Autoimmune Res Lab, San Francisco, CA 94143 USA
Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA
Parker Inst Canc Immunotherapy, San Francisco, CA 94129 USA
Sonoma Biotherapeut, San Francisco, CA 94080 USAUniv Calif San Francisco, Sean N Parker Autoimmune Res Lab, San Francisco, CA 94143 USA
Bluestone, Jeffrey A.
Tang, Qizhi
论文数: 0引用数: 0
h-index: 0
机构:
Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA
Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USAUniv Calif San Francisco, Sean N Parker Autoimmune Res Lab, San Francisco, CA 94143 USA